TNFRSF1A and metabolic disease: Hence, by virtue of their efficient Tnfrsf1a targeting capacity, synthetic 2′-O-methylated miR156c and miR159a mimics may represent valuable therapeutics to reduce inflammation at least in the metabolic diseases associated with adipocyte dysfunction.